Improving Alzheimer's disease drug development

Neurodegeneration There has been considerable investment and effort in developing drugs to slow the progress of Alzheimer's disease, but clinical trials have been disappointing. In a Perspective, Golde et al. discuss the problems that have thwarted Alzheimer's disease drug development, in particular, treating patients too late during disease progression. Efforts to improve treatment and prevention strategies require a mechanism-based approach that also ensures disease progression is followed accurately during clinical trials. Science , this issue p. [1250][1] [1]: /lookup/doi/10.1126/science.aau0437